The 4 analysts offering 12-month price forecasts for Zynerba Pharmaceuticals Inc have a median target of 8.50, with a high estimate of 9.00 and a low estimate of 4.50. The median estimate represents a +141.13% increase from the last price of 3.53.
The current consensus among 5 polled investment analysts is to Buy stock in Zynerba Pharmaceuticals Inc. This rating has held steady since November, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.26
Reporting Date Mar 14
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.